Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors
Lucillia Bezu, Oliver Kepp, Guido Kroemer
Abstract
Recent clinical trials have compared the use of different chemotherapeutic regimens as "immune induction therapies" to sensitize cancers to immune checkpoint inhibitors (ICI). Cytotoxic drugs reputed to be inducers of immunogenic cell death (ICD) appeared to be particularly efficient for this purpose. A trial published in Nature Medicine by Thibaudin et al. reveals the capacity of oxaliplatin-based chemotherapy to sensitize RAS-mutant unresectable metastatic colorectal cancer to ICIs blocking CTLA-4 and PD-L1.
Topics & Concepts
OxaliplatinMedicineColorectal cancerChemotherapyImmune systemCytotoxic T cellImmunogenic cell deathImmune checkpointCancer researchCancerImmunotherapyOncologyImmunologyInternal medicineBiologyIn vitroBiochemistryCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesImmune Cell Function and Interaction